China-based Dizal Pharma will present pivotal data for its first-in-class JAK1 inhibitor golidocitinib and BTK/LYN inhibitor DZD8586 at this year's European Haematology Association (EHA) and International Conference on Malignant Lymphoma (ICML) events.

Golidocitinib demonstrated 74.2% 24-month disease-free survival (DFS) in CR1 peripheral T-cell lymphoma (PTCL) patients and 50% complete response rate (CRR) in partial response patients (median duration of response 23.9 months) in the Phase II JACKPOT26 trial.

DZD8586 showed 84.2% objective response rate (ORR) in heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients, including those with BTK C481X mutations, and 35.5% complete response rate (CRR) in r/r diffuse large B-cell lymphoma (DLBCL).